Vaccination for 5 to 11 year olds: Pfizer-BioNTech requests authorization in Canada

Pfizer-BioNTech on Monday filed its request to Health Canada for approval of the version of its COVID-19 vaccine for children aged 5 to 11, a first in the country for this age group.

• Read also: LIVE | The latest developments on COVID-19

• Read also: Fourth wave: a lull in Quebec, but caution remains in order

The multinational pharmaceutical company submitted its request in the United States on October 7 and in Europe on Friday October 15. According to the “New York Times”, the American health authorities could decide the question at the beginning of November.

The European Medicines Agency (EMA) opened the case on Monday.

“Health Canada will only authorize the use of the Comirnaty vaccine if the independent and comprehensive scientific review of all of the data submitted confirms that the benefits of the vaccine outweigh the risks to this group,” the report said. Federal Ministry in a press release in the afternoon.

It was pointed out that Pfizer-BioNTech is currently conducting studies to develop a version of its vaccine for children under five.

While children in this age group are less likely to have complications from COVID-19 infection, the United States has still recorded nearly 30,000 hospitalizations among those under 18.

As of October 15, Canada had recorded 342,495 cases among those 19 and under, representing 20.6% of total cases.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.